BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements

Reuters

2025/11/12

BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements

BioNexus Gene Lab Corp. (Nasdaq: BGLC) announced that it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. and Tongshu Biotechnology (Hong Kong) Co., Limited to commercialize VitaGuard™, a tumor-naïve liquid-biopsy platform for minimal residual disease (MRD) detection, in Southeast Asia. The agreements include a Share Subscription and Shareholders' Agreement, as well as plans for an IP License Agreement that will grant BGLC exclusive commercialization rights across ASEAN. BGLC is expected to lead regulatory submissions and commercialization efforts, with an initial focus on Singapore and Malaysia. The collaboration aims to support MRD testing development and commercialization in the region through aligned ownership, licensing, and operational support. Completion of the transaction is subject to satisfaction of certain conditions precedent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574033-en) on November 12, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582379236"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582379236\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582379236?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582379236","market":"nz","top_or_hot":-1,"title":"BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BGLC\">BioNexus Gene Lab Corp.</a> (Nasdaq: BGLC) announced that it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. and Tongshu Biotechnology (Hong Kong) Co., Limited to commercialize VitaGuard™, a tumor-naïve liquid-biopsy platform for minimal residual disease (MRD) detection, in Southeast Asia. The agreements include a Share Subscription and Shareholders' Agreement, as well as plans for an IP License Agreement that will grant BGLC exclusive commercialization rights across ASEAN. BGLC is expected to lead regulatory submissions and commercialization efforts, with an initial focus on Singapore and Malaysia. The collaboration aims to support MRD testing development and commercialization in the region through aligned ownership, licensing, and operational support. Completion of the transaction is subject to satisfaction of certain conditions precedent.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574033-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-12 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BGLC\">BioNexus Gene Lab Corp.</a> (Nasdaq: BGLC) announced that it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. and Tongshu Biotechnology (Hong Kong) Co., Limited to commercialize VitaGuard™, a tumor-naïve liquid-biopsy platform for minimal residual disease (MRD) detection, in Southeast Asia. The agreements include a Share Subscription and Shareholders' Agreement, as well as plans for an IP License Agreement that will grant BGLC exclusive commercialization rights across ASEAN. BGLC is expected to lead regulatory submissions and commercialization efforts, with an initial focus on Singapore and Malaysia. The collaboration aims to support MRD testing development and commercialization in the region through aligned ownership, licensing, and operational support. Completion of the transaction is subject to satisfaction of certain conditions precedent.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574033-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BGLC","symbol_name":"BioNexus Gene Lab Corp.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL83YHr:1","article_id":"2582379236","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582379236","pubTimestamp":1762952437,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioNexus Gene Lab Corp.  announced that it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. and Tongshu Biotechnology  Co., Limited to commercialize VitaGuard, a tumor-nave liquid-biopsy platform for minimal residual disease  detection, in Southeast Asia. The agreements include a Share Subscription and Shareholders' Agreement, as well as plans for an IP License Agreement that will grant BGLC exclusive commercialization rights across ASEAN. BGLC is expected to lead regulatory submissions and commercialization efforts, with an initial focus on Singapore and Malaysia. The collaboration aims to support MRD testing development and commercialization in the region through aligned ownership, licensing, and operational support. Completion of the transaction is subject to satisfaction of certain conditions precedent.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BGLC":"BioNexus Gene Lab Corp.","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4104":"贸易公司与经销商"},"translate_title":"BioNexus基因实验室签署东南亚MRD商业化协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGLC":0.9,"NDAQ":0.9},"content_text":"BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements\n    \n\nBioNexus Gene Lab Corp. (Nasdaq: BGLC) announced that it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. and Tongshu Biotechnology (Hong Kong) Co., Limited to commercialize VitaGuard™, a tumor-naïve liquid-biopsy platform for minimal residual disease (MRD) detection, in Southeast Asia. The agreements include a Share Subscription and Shareholders' Agreement, as well as plans for an IP License Agreement that will grant BGLC exclusive commercialization rights across ASEAN. BGLC is expected to lead regulatory submissions and commercialization efforts, with an initial focus on Singapore and Malaysia. The collaboration aims to support MRD testing development and commercialization in the region through aligned ownership, licensing, and operational support. Completion of the transaction is subject to satisfaction of certain conditions precedent.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574033-en) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}